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Abstract 
Background: Although Inflectra, biosimilar infliximab, 
has been approved by the EMA since September 2013 
for all licensed indications of Remicade (innovator 
infliximab) but there is a paucity of real-world data and 
guidelines regarding switching from innovator 
Remicade to Inflectra. 
Objectives: To explore efficacy, safety, and retention 
rate of biosimilar Inflectra when switching from 
Remicade, in patients with rheumatic diseases. 
Methods: Informed consent was sought from all 
patients attending our rheumatology unit to undertake a 
switching programme. Baseline demographics and  
clinical characteristics were obtained before switching 
to Inflectra. Disease activity and safety assessment were 
undertaken before and then every 12 weeks after 
switching. The retention rate of Inflectra switch patients 
was compared with a cohort of non-switch Inflectra 
naive (11 patients) and historic Remicade (31 patients) 
patients. 
Results: Thirty out of thirty-one patients {median (IQR) 
age 50 (18), 20F} with various rheumatic diseases (9 
with diagnosis of AS, 6 with RA, 6 with Behçet’s 
disease, 3 with Enteropathic arthritis, 2 with psoriatic 
arthritis) agreed to the switch. There was no statistical 
difference noted between pre-switch and 6 months post-
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switch mean values of PGA (p=0.37), BASDAI 
(p=0.60), ASDAS-CRP (p=0.90), DAS28CRP (p=0.85), 
DAS28ESR (p=0.45), CRP (p=0.09), Behçet’s disease 
activity score (p=0.77) and HAQ-DI (p=0.18). The 
retention rate on Inflectra switch was 86.7% as 
compared to 90.9% in the Inflectra naive cohort and 
100% for historic Remicade cohort. 
 
Conclusion: These results demonstrate that in this 
cohort at 6 months Inflectra is comparable to Remicade 
in efficacy and there are no new safety signals. 
 
Keywords: Biosimilars; Infliximab; Remicade; 
Inflectra; Rheumatic diseases; Real Life Switching; 
Disease activity; Retention rate; Nocebo effect 
 
1. Introduction 
Undoubtedly biological DMARDs (bDMARDs), 
including TNF-alpha inhibitors, have revolutionized the 
treatment of various rheumatic disorders such as AS, 
RA, and psoriatic arthritis [1-3] and these have become 
an integral component of treatment algorithms of these 
diseases [4, 5]. However huge costs associated with the 
use of bDMARDs have been a barrier to their 
widespread use and accessibility especially in the 
countries with the low gross domestic product [6, 7]. A 
European study has shown that bDMARDs cannot be 
reimbursed in some countries within Europe and 
bDMARDs treatment costs were more than the actual 
GDP in 26 countries [6]. It is anticipated that 
availability of biosimilar DMARDs (bsDMARDs) will 
reduce the economic burden and accessibility to 
biologics due to reduced cost and the addition of 
competition to the market [8]. Biosimilars are biological 
medicinal agents that contain a version of active 
substance of reference biological product, also called 
originator or reference biologics, are supposed to be 
administered at the similar dose to treat same disorders 
[9]. Due to large size and complex structure, an exact 
copy of reference biologic is not possible. There is a 
rigorous process required to establish that a biosimilar 
product is similar to the reference product in terms of 
quality characteristics, biological activity, 
pharmacokinetics, safety, immunogenicity, and efficacy 
[10]. 
 
Inflectra (CT-P13), the biosimilar infliximab, has been 
approved by the European Medicine Agency since 2013 
and for US Food and Drug Administration in 2016 
for all licensed indications of Remicade (innovator 
infliximab) [11]. CT-P13 was authorized was on the 
basis on the basis of randomized controlled trials 
PLANETRA [12] and PLANETAS [13] comparing 
originator infliximab with CT-P13 in rheumatoid 
arthritis and ankylosing spondylitis respectively. 
Approval for other indications (psoriatic arthritis, 
plaque psoriasis, Crohn's disease and ulcerative colitis) 
was based on extrapolation of data from these 
trials, according to guidance for regulatory approval of 
biosimilars [14]. Although Inflectra has been found to 
offer significant cost, there is still a paucity of real-
world data about its safety and efficacy, especially when 
switching from reference infliximab product [15]. 
The aim of our study was to investigate the real-life 
efficacy, safety and retention rate of switching from 
reference infliximab (INX) to biosimilar infliximab 
(CT-P13) in patients with various rheumatic diseases. 
 
2. Methods 
2.1 Patients and study design 
This was a single Centre observational prospective 
cohort study conducted by Department of 
Rheumatology, University Hospitals Limerick at 
rheumatology day ward (infusion center) in Croom 
Orthopedic Hospital. In August 2017, all the patients 
receiving reference infliximab (Remicade™, Janssen 
Biotech, Horsham, PA, USA) for various rheumatic 
diseases were proposed to switch to 
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biosimilar infliximab CT-P13 (Inflectra™, Lake Forest, 
IL, USA). Ethical approval was obtained from the local 
ethics committee to undertake this study. All these 
patients were physically interviewed by Rheumatology 
registrar to discuss switching and they were given 
information about biosimilar infliximab and data about 
its safety and efficacy. Informed consent was obtained 
from all the patients agreeing to participate. Patients 
were also informed about the option of switching back 
to reference infliximab in future if necessary. Any 
patient receiving reference infliximab was considered 
eligible for the study. The patients who agreed to switch 
were started on CT-P13 at the same treatment regimen 
(dose and frequency) after getting written 
consent. Associated treatments including csDMARDs 
and corticosteroids were not modified at inclusion. 
For comparison of retention rate, two control cohorts 
from the same department were used: 
1) A cohort of Inflectra-naïve (non-switch Inflectra 
patients). These were 11 patients who were started on 
Inflectra and they were never on Remicade.  
2) A retrospective cohort of 31patients who were treated 
with Remicade during Ist half of the year 2017.  
 
The primary outcome was to compare efficacy and 
safety indicators before the switch (on 
reference infliximab) and 6 months post-treatment with 
biosimilar infliximab. The secondary outcome was to 
compare retention rate of switch population of 
biosimilar infliximab with biosimilar infliximab naive 




Demographic, clinical and laboratory 
data were obtained pre-switch and then clinical and 
laboratory data were obtained at median 12 weeks 
follow up. This data included age, sex, rheumatologic 
diagnosis, duration of disease, comorbidities, 
vaccination status, seropositivity, current treatment, 
duration of infliximab therapy, concomitant 
immunosuppressive therapy, previous failed 
csDMARDs or bDMARDs, DAS28 CRP, DAS28 ESR, 
SDAI, tender joint count, swollen joint count, BADSAI, 
ASDAS CRP, Behçet’s disease activity index (BD 
score), health assessment questionnaire disability index 
(HAQ-DI), patient global assessment (PGA) and side 
effects. Laboratory data included inflammatory markers, 
bone profile, Vit D, U and Es, LFTs and FBC. 
 
2.3 Statistical analysis 
The data were analysed using SPSS version 22. 
Descriptive statistics were used to report differences in 
patient demographics and disease characteristics 
between Inflectra switch population and Inflectra naive 
cohort. Normally distributed data were expressed as 
mean (Standard deviation) while nonnormally 
distributed data was shown as median (range or 
interquartile range, IQR). Pre-switch and 6 months post-
switch disease activity measures were compared using 
paired sample t-test. p values below 0.05 were 
considered significant. Kaplan-Meier survival curves of 
retention rate were compared using a log-rank test. 
 
3. Results 
3.1 Population characteristics 
Thirty out of thirty-one patients on Remicade agreed to 
switch to Inflectra. Patients’s disease and treatment 
characteristics are elaborated in Table 1. Among switch 
population, 9 patients (30%) had ankylosing spondylitis 
(4 were HLA B27 Positive), 6 patients (20%) had RA (4 
were seropositive for RF and Anti-CCP), 6 (20%) had 
Behçet’s disease, 2 (6.7%) had psoriatic arthritis and 3 
(10%) patients had Enteropathic arthritis. Their mean 
age was 50 (12.2) years and 20 (66.7%) were female. 
Mean duration of disease was 6.8 (2.9) years and 
median duration of being on Remicade prior to switch 
was 72 (24-192) months. More than half of the patients 
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(53.3%) were on csDMARDs and nearly one third 
(30%) were on corticosteroids along with Infliximab. 
Among 11 patients of non-switch Inflectra cohort, five 
patients (45.5%) had psoriatic arthritis, 3 (27.3%) had 
RA and one (9.1%) had AS. Their mean age was 47.2 
(15.2) years and 6 (54.5%) were female. Mean duration 
of disease was 8 (5.2) years and median duration of 
being on Remicade prior to switch was 11 (2-
26) months. More than half of the patients (53.3%) were 
on csDMARDs and nearly one third (30%) were on 
corticosteroids along with Infliximab. 6 (54.5%) 




Pre-switch disease activity measures of Inflectra switch 
population were compared with 6 months post-switch 
disease activity measures of the same patients (Figure 
1). Mean (standard deviation) PGA pre-switch was 33 
(26.3) compared to 35.3 (24) following biosimilar 
switching without significant difference (p=0.37). Mean 
HAQ on reference infliximab also did not differ 
significantly following switching {0.42 (0.45) vs 0.45 
(0.47) p=0.18}. Rheumatoid arthritis, ankylosing 
spondylitis and psoriatic arthritis patients didn't show 
any statistically significant worsening in disease activity 
measures following the switch as shown by mean values 
of BASDAI (3.12 (1.2) vs 2.98 (1.5) p=0.60}, ASDAS-
CRP{1.7 (0.57) vs 1.7 (0.57) p=0.90}, SDAI {14.6 
(16.5) vs 13.1 (10.4) p=0.65}, DAS28CRP {3.9 (1.6) vs 
3.28 (1.0) p=0.85}, DAS28ESR {3.97 (2.04) vs 3.49 
(1.20) p=0.45}, CRP {3.13 (4.2) vs 3.48 (4.8) p=0.09}. 
Our cohort of Behçet’s disease patients also maintained 
their efficacy following switch to biosimilar (mean 
Behçet’s disease activity index 1.17 (1.3) vs 1.33 (2.16) 
p=0.77). 
 
3.3 Retention rate and safety 
At 6 months post-switch, 26 (86.7%) out of 30 patients 
are continuing Inflectra with good efficacy and without 
any serious safety concern. This retention rate is lower 
than that of the cohorts of historic Remicade (100%) 
and Inflectra (90.9%) Figure 2. All 4 patients who 
stopped Inflectra were successfully switched back to 
Remicade. Among these four drop-outs, one patient 
developed severe nausea, dizziness and abdominal pain 
after her first Inflectra infusion and another patient 
developed psoriasis flare 12 weeks after the switch 
(having had no active psoriasis for the years they were 
on Remicade). Two patients developed subjective 
worsening of pain without objective or serological 
worsening of disease activity (Figure 3). One patient 
among Inflectra naive group had to stop Inflectra 
because of recurrent chest infections. No patients on 
Inflectra developed serious infections requiring hospital 
admission. These 4 patients were successfully switched 
back to Remicade. Patient 1 with nausea and abdominal 
pain had no further symptoms. Patient 2 with flare of 
psoriasis had full clearing of psoriasis within 2 months 
of switching back and 2 patients with subjective flare of 
symptoms reported a return to pre-switching symptom 
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Characteristics at inclusion Inflectra switch population (n=30) Inflectra-naïve (non-switch) 
population (n=11) 
Age, years, mean (S.D.) 50 (12.2) 47.2 (15.2) 
Female Sex 20 (66.7%) 6 (54.5%) 






AS 9 (30%) 1 (9.1%) 
Behçet’s disease 6 (20%) 1 (9.1%) 
Psoriatic Arthritis 2 (6.7%) 5 (45.5%) 
Enteropathic Arthritis 3 (10%) 0 
JIA 1 (3.3%) 0 
Undifferentiated 
inflammatory arthritis 
1 (3.3%) 0 
Juvenile Dermatomyositis 1 (3.3%) 0 
GCA 0 1 (9.1%) 
Graves Ophthalmopathy 1 (3.3%) - 
Disease duration mean years (S.D.) 6.8 (2.9) 8 (5.2) 
Weight, Kgs, mean (S.D.) 72.4 (10.5) 94.2 (30.9) 
Height, centimeters, mean (S.D.) 166.5 (9.1) 165.9 (8.4) 
BMI, kg/m², mean (S.D.) 26.1 (3.5) 34.5 (11.8) 
Infliximab dose, mg/kg, median 
(range) 
5 (3-8) 5 
Infliximab infusion frequency, 
median (range) 
6 (4-12) 6 (6-8) 
Duration of being on Infliximab 
before switch, months, median 
(range) 
72 (24-192) 11 (2-26) 
Concomitant csDMARDs, n (%) 16 (53.3%) 6 (54.5%) 
Methotrexate, dose, mg, median 
(range) 
15 (10-25) 15 (10-25) 
Concomitant corticosteroids, n (%) 9 (30%) 6 (54.5%) 
Previously been on other 
bDMARDS, n (%) 
19 (63.3%) 11 (100%) 
RA: Rheumatoid Arthritis; AS: Ankylosing Spondylitis; JIA: Juvenile Idiopathic Arthritis; GCA: Giant Cell 
Arteritis; SD: Standard Deviation; BMI: Body Mass Index; csDMARDs; Conventional Synthetic Disease Modifying 
Anti-Rheumatic Drugs; bDMARDs: Disease Modifying Anti-Rheumatic Drugs. 
 
Table 1: Baseline characteristics of Inflectra switch and Inflectra naïve (|non-switch) patients’ groups. 
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PGA: Patient global assessment score; BADSAI: Bath Ankylosing Spondylitis Disease Activity Index; ASDAS-
CRP: Ankylosing Spondylitis Disease Activity Score-C reactive protein; SDAI: Simplified Disease Activity Index; 
DAS28CRP: Disease Activity Score 28- C reactive protein; DAS28ESR: Disease Activity Score 28- Erythrocyte 
Sedimentation Rate; TJC: Tender joint count; SJC: Swollen Joint Count; BD score: Behcet disease activity index; 
HAQ-DI: health assessment questionnaire- disability index 
 
Figure 1: Box plots to compare main study outcomes pre-switch and 6 months post-switch. 
 
 
Figure 2: Comparison of 6 months retention rate among Inflectra switch, Inflectra Naïve (Inflectra non-switch) and 
Historic Remicade groups. 
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Figure 3: Flowsheet showing outcome of switch population at 6 months. 
 
4. Discussion 
Our study is one of only a few studies done in real-life 
setting examining efficacy and safety of switching from 
reference infliximab (Remicade) to biosimilar 
infliximab, CT-P13 (Inflectra). It clearly shows that the 
clinical efficacy and tolerability of Inflectra is 
equivalent to Remicade even after switching in a real-
life setting; supporting data from previous randomised 
controlled trials and observation single and multicentre 
studies. PLANETAS [12], a phase I RCT, confirmed 
pharmacokinetic equivalence of CT-P13 and reference 
infliximab without any significant difference in disease 
activity and safety measures at week 30. Bio clinical 
equivalence was demonstrated by PLANETRA [13], a 
phase III RCT, which showed comparable ACR20 
responses at week 30: 60.9% for CT-P13, 58.6% for 
reference infliximab (95% CI, −6% to 10%). 54 weeks 
results of these trials demonstrated persistent disease 
activity without any safety concerns [16, 17]. In the 
extension phase of PLANETRA [18] and PLANETAS 
[19], patients who received reference infliximab 
were switched to CT-P13 at week 52 and compared to 
the group receiving CT-P13 from the beginning. After 
an additional year of follow-up, there was no difference 
in terms of efficacy and tolerance as shown by 
comparable ACR 20, ACR 40, ACR 70, ASAS 20 and 
ASAS 40 responses. The NOR-SWITCH, a 
Norwegian study, was 52-week randomized double-
blind, non-inferiority, phase IV trial [20]. In this trial, 
482 patients of inflammatory bowel disease and various 
rheumatic disease were randomised in a 1:1 ratio to 
either continued infliximab originator or to switch to 
CT-P13 treatment. At 52 weeks, CT-P13 was found to 
be non-inferior to reference infliximab with the 
predefined non-inferiority margin of 15%.  
 
The Danish DABINO registry published results of 802 
patients with RA (403), SpA (279), PsA (120) who 
underwent a non-medical switch to CT-P13 from 
reference Infliximab [21]. These results showed similar 
disease activity and flares 3 months before and 3 
months after the switch for the three diseases. The 
retention rate at 1 year was 84% for CT-P13 and 86% 
for reference infliximab. A single Centre observational 
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real-life French study examined the weight of 
patient acceptance and retention rate of CT-P13 for 
patients with various rheumatic diseases [22]. After a 
median follow-up of 33 weeks, the retention rate was 
significantly lower in CT-P13 switch cohort (72%) as 
compared to the prospective CT-P13 naive cohort 
(88%) and retrospective historic reference infliximab 
cohorts (90%). Data from a local, single 
Centre observational study showed the CT-P13 
retention rate of 85.3% at 6 months [23]. It is important 
to note that 2 0f 30 patients (13%) did have an objective 
adverse outcome from switching. One patient developed 
nausea and abdominal pain and the second a flare of 
long quiescent psoriasis. All four patients switched back 
to Remicade did so successfully which is reassuring, but 
the cases noted remind us that Biosimilars medications 
are not Generic and there are significant and relevant 
differences between biosimilar and bio-originator 
products. 
 
Among all observational switch studies, our trial 
showed the best retention rate 86.7% at 6 months. 
Subjective reasons were the most important reason 
(50%) of dropouts. This can be due to nocebo effects of 
non-medical infliximab switch. A nocebo effect occurs 
when patient’s negative perception of treatment causes 
an unexplained worsening of disease outcome. 
Significant price difference between bio-originators and 
biosimilars can also be a leading factor resulting in 
negative perception and nocebo effect. Our strategy of 
patient empowerment could be one of the factors 
contributing towards high retention rate of CT-P13. The 
nocebo effect associated with non-medical infliximab 
switch was studied in a recently published Dutch study 
[24]. Our cohort of Behçet’s disease patients 
[25] maintained good disease control after switching to 
CT-P13. This is first real-time study showing efficacy 
of CT-P13 in Behçet’s disease patients. The main 
strengths of our study were that it was conducted in 
real-life clinical setting on a wide variety rheumatology 
patient and we used two other cohorts to compare 
retention rate of switch population. The small number of 
patients, being observational rather than randomised and 
short follow-up were main limitations of our study. 
 
5. Conclusion 
Based on the results of our real-life clinical study, we 
are satisfied that CT-P13 is a safe and efficacious option 
to treat a variety of rheumatology patients and it is 
reassuring that switching to CT-P13 can lead to 
substantial savings essential for the sustainability of the 
healthcare system. Switching back to Remicade where 
necessary was effective and safe. Randomised 
controlled trials are required to prove long-term safety 
and efficacy of CT-P13 with higher patient number and 
longer-term follow-up.  
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